CLINICAL_TRIALS
trial_result
· 2022-04-11
Clinical Trial Update: Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures [Phase 2]
Summary
Phase 2 trial update on YKP3089 for treatment-resistant partial onset seizures; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: SK Life Science, Inc. | Conditions: Partial Epilepsy | Phase 2 | Status: COMPLETED | Results posted: 2022-04-11